Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Annals of Hematology

Volumn 92, Issue 4, 2013, Pages 487-496

  Oyekunle, Anthony ^a,b   Zander, Axel R ^a   Binder, Mascha ^a   Ayuk, Francis ^a   Zabelina, Tatjana ^a   Christopeit, Maximilian ^c   Stübig, Thomas ^a   Alchalby, Haefaa ^a   Schafhausen, Philippe ^a   Lellek, Heinrich ^a   Wolschke, Christine ^a   Müller, Ingo ^a,d   Bacher, Ulrike ^a,e   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Advanced CML; Allogeneic stem cell transplantation (SCT); Chronic myeloid leukemia (CML); Prognosis; Tyrosine kinase inhibitors (TKIs)

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME; ADOLESCENT; ALLOTRANSPLANTATION; COHORT ANALYSIS; DRUG ANTAGONISM; EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877028031     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1650-8     Document Type: Article

References (32)

1. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D (2007) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-4011
2. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M (2007) Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Cancer 110(2):340-344
3. Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H, Ehninger G, Muller C, Berger J, Suttorp M, Kolb HJ, Kroger N, Zander AR (2009) The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia - a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 88(12):1237-1247
4. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91(4):513-521
5. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-6051
6. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352(9134):1087-1092
7. Guglielmi C, Arcese W, Hermans J, Bacigalupo A, Bandini G, Bunjes D, Carreras E, Devergie A, Frassoni F, Goldman J, Gratwohl A, Kolb HJ, Iori AP, Niederwieser D, Prentice HG, de Witte T, Apperley J (2000) Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 95(11):3328-3334
8. Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H (1998) Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(12):3782-3787
9. Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E, Deeg H, Doney K, Fisher L, Hansen J (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84(6):2036-2043
10. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-397
11. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM (2012) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (in press). doi: 10.1038/leu.2012.181
12. Klyuchnikov E, Kröger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U (2010) Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biol Blood Marrow Transpl 16(3):301-310
13. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R, German CML Study Group (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880-1885
14. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A (2006) EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transpl 37(12):1069-1085
15. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prise PY, Beauplet A, Bories D, Semana G, Quelvennec E (2002) Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99(12):4618-4625
16. Fehse B, Chukhlovin A, Kuhlcke K, Marinetz O, Vorwig O, Renges H, Kruger W, Zabelina T, Dudina O, Finckenstein FG, Kroger N, Kabisch H, Hochhaus A, Zander AR (2001) Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 10(3):419-425
17. Oyekunle A, Klyuchnikov E, Ocheni S, Kroger N, Zander AR, Baccarani M, Bacher U (2011) Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 126(1):30-39
18. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM (2007) Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 137(5):461-467
19. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM (2005) Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19(6):990-997
20. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106(9):2969-2976
21. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809-1820
22. El-Alfy MS, Al-Haddad AM, Hamed AA (2010) Management of CML in the pediatric age group: imatinib mesylate or SCT. J Egypt Natl Canc Inst 22(4):227-232
23. Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology 2010(1):368-376. doi: 10.1182/asheducation-2010.1. 368
24. Suttorp M, Eckardt L, Tauer J, Millot F (2012) Management of chronic myeloid leukemia in childhood. Curr Hematol Malig Rep 7(2):116-124
25. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23(18):4100-4109
26. Krieger O (2010) Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option? Mag Eur Med Oncol 3(1):16-18
27. Gratwohl A, Heim D (2009) Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):431-443
28. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117(11):3032-3040
29. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-1987
30. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ (2012) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transpl 47(6):810-816
31. Gaziev D, Galimberti M, Lucarelli G, Polchi P, Giardini C, Angelucci E, Baronciani D, Sodani P, Erer B, Biagi MD, Andreani M, Agostinelli F, Donati M, Nesci S, Talevi N (2000) Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transpl 25(8):815-821
32. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A, Runde V, Grosse-Wilde H, Beelen DW, Schaefer UW (2002) Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99(4):1130-1135